Patients with hemophilia without inhibitors can expect excellent outcomes with the currently available factor replacement therapy. Studies have demonstrated that patients with severe hemophilia on prophylaxis can have completely normal joints well into adulthood. This tremendously successful treatment however does not apply to patients who develop neutralizing antibodies—so-called inhibitors—that render standard factor replacement ineffective. Such patients still suffer from serious bleeding complications and often develop debilitating joint disease. This symposium will focus on recent advances in the management of inhibitor patients. The first lecture will examine inhibitor eradication and will include a discussion on the current state of immune tolerance as well as a brief discussion on immunosuppression. The second lecture will discuss treatment of bleeding episodes including a discussion of the recently published data on selection and dosing of bypassing agents as well as combination therapy with bypassing agents. The final hour will be dedicated to a discussion of prophylaxis in inhibitor patients and will be done in a debate format with two speakers debating the merits of FEIBA and rFVIIa for prophylaxis of bleeding episodes.